Gamma-aminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment.
Gamma-aminobutyric acid (GABA) levels in the CSF were measured in 9 normal individuals, 17 drug-free schizophrenic patients and 10 of these same schizophrenic patients after neuroleptic treatment. There was no significant difference between CSF level of GABA in the control group compared to those in schizophrenic patients; however, 6 of the 7 lowest GABA levels were from schizophrenic patients. There was a significant decline of 12 per cent in mean GABA levels in the CSF after a mean of two months of neuroleptic treatment.
D000328:Adult; D000613:Aminobutyrates / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000134:cerebrospinal fluid*
D000613:Aminobutyrates; D014149:Tranquilizing Agents; D005680:gamma-Aminobutyric Acid